UK markets close in 7 hours 42 minutes
  • FTSE 100

    7,355.55
    +18.50 (+0.25%)
     
  • FTSE 250

    23,271.15
    +40.72 (+0.18%)
     
  • AIM

    1,199.89
    +0.20 (+0.02%)
     
  • GBP/EUR

    1.1666
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.3207
    0.0000 (-0.00%)
     
  • BTC-GBP

    37,560.81
    -774.78 (-2.02%)
     
  • CMC Crypto 200

    1,296.32
    -8.80 (-0.67%)
     
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • DOW

    35,754.75
    +35.32 (+0.10%)
     
  • CRUDE OIL

    72.42
    +0.06 (+0.08%)
     
  • GOLD FUTURES

    1,785.00
    -0.50 (-0.03%)
     
  • NIKKEI 225

    28,725.47
    -135.15 (-0.47%)
     
  • HANG SENG

    24,254.86
    +257.99 (+1.08%)
     
  • DAX

    15,719.27
    +32.18 (+0.21%)
     
  • CAC 40

    7,042.27
    +27.70 (+0.39%)
     

Doseology Set to Trade CSE: MOOD

·5-min read

DGAP-News: Doseology Sciences Inc.
15.11.2021 / 14:00
The issuer is solely responsible for the content of this announcement.

Doseology Sciences Inc. (CSE: MOOD) ('Doseology' or the 'Company') is pleased to announce that its shares will begin trading on the CSE today and has retained Hybrid Financial Ltd. ('Hybrid') to provide marketing and call centre services to the Company.

Hybrid has agreed to comply with all applicable securities laws and the policies of the Canadian Securities Exchange (the 'CSE') in providing their services.

Hybrid has been engaged by the Company for an initial period of six (6) months starting from November 15, 2021 (the 'Initial Term') and shall be renewed for an additional six (6) months thereafter, unless terminated by the Company in accordance with the Agreement. Hybrid will be paid a monthly fee of $22,500 plus applicable taxes, during the Initial Term.

Daniel Vice, CEO and Director commented, 'We look forward to Hybrid amplifying market awareness to the Doseology brand and broadening the Company's reach within the investment community'.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful.

On Behalf of the Board of Directors

Doseology Sciences Inc.

Daniel Vice

Chief Executive Officer and Director

About Doseology Sciences Inc.

Doseology is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

About Hybrid Financial Ltd.

Hybrid is a sales and distribution company that actively connects issuers to the investment community across North America. Using a data driven approach, Hybrid provides its clients with comprehensive coverage of both American and Canadian markets, Hybrid Financial offices in Toronto, and Montreal.

FOR FURTHER INFORMATION CONTACT:

Investor Relations

Email: investor@doseology.com

Telephone: 236-349-0064

Website: www.doseology.com

Forward Looking Statements

This press release contains statements which constitute 'forward-looking information' within the meaning of applicable securities laws. Forward-looking information is often identified by the words 'may,' 'would,' 'could,' 'should,' 'will,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'expect' or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company's securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

Contact Details

Investor Relations

+1 236-349-0064

investor@doseology.com


News Source: News Direct


15.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Doseology Sciences Inc.

United States

ISIN:

CA2584841043

EQS News ID:

1249110


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting